Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Completed 4Unknown 2Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Thromboembolism 1Pulmonary Embolism 1Pancreatic Neoplasms 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Tinzaparin × Clear all
NCT05178628 2022-03-29

imPaCT-PRO

Institute of Molecular Medicine and Biomedical Research

Phase 3 Unknown
450 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

NCT03240120 2019-04-17

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

The University of Hong Kong

Phase 3 Unknown
99 enrolled
Classical hematology

Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡